News | February 20, 2022
Syncona completes sale of Gyroscope to Novartis
The transaction generates upfront cash proceeds of $442 million for Syncona's holding in Gyroscope
The transaction generates upfront cash proceeds of $442 million for Syncona's holding in Gyroscope
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
Data from the Phase 2b QUASAR Induction Study showed approximately 60% of patients achieved the primary endpoint of clinical response, and approximately 30% showed endoscopic improvement with TREMFYA treatment compared with placebo
Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
Recall does not include any metabolic deficiency nutrition formulas
The Healthcare Technology Report provides market research and insights, business news, investment activity updates and important corporate developments related to the healthcare technology sector
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Suvinys Developers will supply dydrogesterone to Jagsonpal Pharma as per the terms and conditions mentioned in the agreement.
Subscribe To Our Newsletter & Stay Updated
